A feasibility study of neoadjuvant chemotherapy with docetaxel+cisplatin+capecitabine (DCX) for HER2-negative gastric cancer with macroscopic type 4 and large type 3, or with multiple lymph node metastasis - A feasibility study of neoadjuvant chemotherapy with docetaxel+cisplatin+capecitabine (DCX) for HER2-negative gastric cancer with macroscopic type 4 and large type 3, or with multiple lymph node metastasis

agoya University0 个研究点目标入组 20 人开始时间: 2017年5月1日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1) HER2 IHC 3+, or IHC 2 and FISH+ 2) Uncontrolled diabetes 3) Uncontrolled hypertension 4) Unstable angina pectoris, or a history of myocardial infarction within six months 5) Chronic lung disease: interstitial pneumonia, pulmonary fibrosis, or severe emphysema 6) Synchronous cancers (except for cases whose prognositc facter is gastric cancer) 7) Systemic infection requiring treatment 8) Fever above 38 degree Celsius 9) A possibility of pregnancy or during pregnancy, or lactating women 10) Psychosis or psychotic symptoms 11) Continuous systemic administration of steroids (oral or intravenous)

发起方

agoya University